این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
Research in Pharmaceutical Sciences، جلد ۱۲، شماره ۱، صفحات ۶۰-۶۶
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی In silico designing of a new cysteine analogue of hirudin variant 3 for site specific PEGylation
چکیده انگلیسی مقاله Hirudin is an anticoagulant agent of the salivary glands of the medicinal leech. Recombinant hirudin (r-Hir) displays certain drawbacks including bleeding and immunogenicity. To solve these problems, cysteine-specific PEGylation has been proposed as a successful technique. However, proper selection of the appropriate cysteine residue for substitution is a critical step. This study has, for the first time, used a computational approach aimed at identifying a single potential PEGylation site for replacement by cysteine residue in the hirudin variant 3 (HV3). Homology modeling (HM) was performed using MODELLER. All non-cysteine residues of the HV3 were replaced with the cysteine. The best model was selected based on the results of discrete optimized protein energy score, PROCHECK software, and Verify3D. The receptor binding was investigated using protein-protein docking by ClusPro web tool which was then visualized using LigPlot+ software and PyMOL. Finally, multiple sequence alignment (MSA) using ClustalW software and disulfide bond prediction were performed. According to the results of HM and docking, Q33C, which was located on the surface of the protein, was the best site for PEGylation. Furthermore, MSA showed that Q33 was not a conserved residue and LigPlot+ software showed that it is not involved in the hirudin-thrombin binding pocket. Moreover, prediction softwares established that it is not involved in disulfide bond formation. In this study, for the first time, the utility of the in silico approach for creating a cysteine analogue of HV3 was introduced. Our study demonstrated that the substitution of Q33 by cysteine probably has no effect on the biological activity of the HV3. However, experimental analyses are required to confirm the results.
کلیدواژه‌های انگلیسی مقاله In silico,Hirudin variant 3,PEGylation
نویسندگان مقاله سید مهدی سجادی | seyed mehdi sajjadi
1 cellular and molecular research center, birjand university of medical sciences, birjand, i.r. iran.

سازمان اصلی تایید شده: دانشگاه علوم پزشکی بیرجند (Birjand university of medical sciences)

حمزه رحیمی | hamzeh rahimi
2molecular medicine group, biotechnology research center, pasteur institute of iran, tehran, i.r. iran.

سازمان اصلی تایید شده: انستیتو پاستور ایران (Pasteur institute of iran)

سعید محمدی | saeed mohammadi
3hematology, oncology and stem cell transplantation research center, tehran university of medical sciences, tehran, i.r. iran.

سازمان اصلی تایید شده: دانشگاه علوم پزشکی تهران (Tehran university of medical sciences)

محمد فرانوش | mohammad faranoush
4rasoul akram medical center, iran university of medical sciences, tehran, i.r. iran.

سازمان اصلی تایید شده: دانشگاه علوم پزشکی ایران (Iran university of medical sciences)

حسن میرزاحسینی | hasan mirzahoseini
5biotechnology group, biotechnology research center, pasteur institute of iran, tehran, i.r. iran.

سازمان اصلی تایید شده: انستیتو پاستور ایران (Pasteur institute of iran)

غلامرضا توگه | gholamreza toogeh
6thrombosis and homeostasis research center, imam khomeni hospital complex, tehran university of medical sciences, tehran, i.r. iran.

سازمان اصلی تایید شده: دانشگاه علوم پزشکی تهران (Tehran university of medical sciences)

نشانی اینترنتی http://rps.mui.ac.ir/index.php/jrps/article/view/1744
فایل مقاله اشکال در دسترسی به فایل - ./files/site1/rds_journals/115/article-115-350615.pdf
کد مقاله (doi)
زبان مقاله منتشر شده en
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده Original Article
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات